Jennifer Wargo, MD
MD Anderson Cancer Center
Dr. Jennifer Wargo is an internationally recognized physician-scientist whose career has been dedicated to advancing the understanding and treatment of cancer through innovative translational research. With a profound commitment to bridging science and patient care, Dr. Wargo’s work has fundamentally reshaped approaches to cancer therapy, setting new paradigms in the fields of immunotherapy, targeted therapy, and microbiome research.
Dr. Wargo earned her medical degree and completed surgical residency training at Massachusetts General Hospital (MGH), where she developed a keen interest in cancer biology and therapy. During her training, she completed two fellowships in surgical oncology with a focus on cancer immunotherapy, laying the foundation for her impactful career. In 2008, she was recruited to join the faculty in the Division of Surgical Oncology at MGH, where she established a translational research laboratory aimed at understanding response and resistance to treatment in melanoma, pancreatic cancer, and other malignancies. Her pioneering work during this time demonstrated that molecularly targeted therapy could sensitize tumor cells to immunotherapy, providing a scientific rationale for combining these treatment modalities—a strategy now being evaluated in clinical trials with promising outcomes.
In 2013, Dr. Wargo was recruited to the University of Texas MD Anderson Cancer Center to help lead the institution’s Melanoma Moonshot efforts. Today, she serves as a Professor of Surgical Oncology and Genomic Medicine and leads the Platform for Innovative Microbiome and Translational Research (PRIME-TR). Her groundbreaking research continues to focus on enhancing cancer therapies through targeted therapy, immunotherapy, and modulation of the gut and tumor microbiome. Recognized globally for her discoveries, Dr. Wargo has made paradigm- and practice-changing contributions to understanding how the microbiome influences cancer treatment responses. Her team’s work has shown that diet, particularly a high-fiber intake, and strategies modulating gut microbes can improve patient outcomes—insights that have spurred new clinical trials and opened an entirely new field of research.
Throughout her career, Dr. Wargo has identified novel biomarkers and therapeutic targets that have been widely published in leading journals such as Nature, Nature Medicine, Science, Cell, Cancer Discovery, and Lancet Oncology. She pioneered the use of neoadjuvant targeted therapy and immune checkpoint blockade in melanoma and other cancers and cofounded the International Neoadjuvant Melanoma Consortium to further collaborative progress in the field.
Dr. Wargo’s contributions to understanding the immune effects of targeted therapy, especially in melanoma, have been instrumental in defining mechanisms of treatment resistance and developing strategies to overcome them. Early in her career, she co-authored seminal papers that identified resistance mechanisms to BRAF-targeted therapies, and she led efforts to collect longitudinal tumor biopsies and blood samples for deep molecular analyses—work that enabled the discovery of numerous resistance pathways and informed new therapeutic strategies.
As a dedicated collaborator and inspirational servant leader, Dr. Wargo is deeply committed to working with investigators across disciplines and around the world to develop innovative strategies to treat, intercept, and ultimately prevent cancer. Her visionary research continues to push the boundaries of cancer science, improving the lives of patients worldwide.
Dr. Wargo earned her medical degree and completed surgical residency training at Massachusetts General Hospital (MGH), where she developed a keen interest in cancer biology and therapy. During her training, she completed two fellowships in surgical oncology with a focus on cancer immunotherapy, laying the foundation for her impactful career. In 2008, she was recruited to join the faculty in the Division of Surgical Oncology at MGH, where she established a translational research laboratory aimed at understanding response and resistance to treatment in melanoma, pancreatic cancer, and other malignancies. Her pioneering work during this time demonstrated that molecularly targeted therapy could sensitize tumor cells to immunotherapy, providing a scientific rationale for combining these treatment modalities—a strategy now being evaluated in clinical trials with promising outcomes.
In 2013, Dr. Wargo was recruited to the University of Texas MD Anderson Cancer Center to help lead the institution’s Melanoma Moonshot efforts. Today, she serves as a Professor of Surgical Oncology and Genomic Medicine and leads the Platform for Innovative Microbiome and Translational Research (PRIME-TR). Her groundbreaking research continues to focus on enhancing cancer therapies through targeted therapy, immunotherapy, and modulation of the gut and tumor microbiome. Recognized globally for her discoveries, Dr. Wargo has made paradigm- and practice-changing contributions to understanding how the microbiome influences cancer treatment responses. Her team’s work has shown that diet, particularly a high-fiber intake, and strategies modulating gut microbes can improve patient outcomes—insights that have spurred new clinical trials and opened an entirely new field of research.
Throughout her career, Dr. Wargo has identified novel biomarkers and therapeutic targets that have been widely published in leading journals such as Nature, Nature Medicine, Science, Cell, Cancer Discovery, and Lancet Oncology. She pioneered the use of neoadjuvant targeted therapy and immune checkpoint blockade in melanoma and other cancers and cofounded the International Neoadjuvant Melanoma Consortium to further collaborative progress in the field.
Dr. Wargo’s contributions to understanding the immune effects of targeted therapy, especially in melanoma, have been instrumental in defining mechanisms of treatment resistance and developing strategies to overcome them. Early in her career, she co-authored seminal papers that identified resistance mechanisms to BRAF-targeted therapies, and she led efforts to collect longitudinal tumor biopsies and blood samples for deep molecular analyses—work that enabled the discovery of numerous resistance pathways and informed new therapeutic strategies.
As a dedicated collaborator and inspirational servant leader, Dr. Wargo is deeply committed to working with investigators across disciplines and around the world to develop innovative strategies to treat, intercept, and ultimately prevent cancer. Her visionary research continues to push the boundaries of cancer science, improving the lives of patients worldwide.
